-
Mashup Score: 2High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy - 1 month(s) ago
Immunology; Molecular biology; Cancer
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 37What it feels like: Taking a colorectal cancer diagnosis and turning it into hope for others - 1 month(s) ago
Barry Stein first noticed blood in his stool when he was in his 30s and didn’ t think much of it. After further reflection, Stein thought that checking things out may not be such a bad idea. That inkling to seek out medical testing could be what saved Barry Stein’s life: shortly after that, he was diagnosed with early-onset colorectal cancer. Unfortunately, the cancer was no longer confined to his colon, as it had begun spreading to other areas of the body. Because of that, and the lack of viable treatment
Source: www.healthing.caCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 47Outcome differences by sex in oncology clinical trials - 1 month(s) ago
Nature Communications – The role of sex differences in response to cancer therapy remains unclear but this could be improved by reporting sex comparisons of outcomes in clinical trials. Here, the…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20OX40/OX40 ligand and its role in precision immune oncology - PubMed - 1 month(s) ago
Immune checkpoint inhibitors have changed the treatment landscape for various malignancies; however, their benefit is limited to a subset of patients. The immune machinery includes both mediators of suppression/immune evasion, such as PD-1, PD-L1, CTLA-4, and LAG-3, all of which can be inhibited by …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20OX40/OX40 ligand and its role in precision immune oncology - PubMed - 1 month(s) ago
Immune checkpoint inhibitors have changed the treatment landscape for various malignancies; however, their benefit is limited to a subset of patients. The immune machinery includes both mediators of suppression/immune evasion, such as PD-1, PD-L1, CTLA-4, and LAG-3, all of which can be inhibited by …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 45
Cancer is traditionally diagnosed and treated on the basis of its organ of origin (e.g., lung or colon cancer). However, organ-of-origin diagnostics does not reveal the underlying oncogenic drivers. Fortunately, molecular diagnostics have advanced at a breathtaking pace, and it is increasingly appar …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 36
We read with great interest the report by Watson et al 1 describing in detail a case of hyperprogression (HPD) after pembrolizumab in Epstein-Barr virus-associated gastric adenocarcinoma (EBVaGC). We congratulate the authors for the diligent work presented in evaluating clinical, immunohistochemical, molecular, and immunologic features of this patient’s tumor to elaborate on potential explanations for HPD seen in the subtype of EBVaGC, typically associated with significant response to immune checkpoint
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
RT @waraonc23: https://t.co/sd8D8PTsBC Let me re-post! Our work dissecting mRNA expression of immune markers is now available! @iScience_C…